Asuragen QuantideX BCR-ABL tests
qPCR molecular methods to help advance our understanding of cancer
The Asuragen Oncology portfolio uses proprietary molecular chemistry and informatics solutions to deliver critical clinical research insights that drive the evolution of therapy, patient monitoring and precision medicine.
QuantideX qPCR BCR-ABL IS
The QuantideX® qPCR BCR-ABL IS Kit is intended for chronic myeloid leukemia (CML) monitoring. It’s a qPCR-based in vitro Diagnostic test for the quantitation of BCR-ABL1 and ABL1 transcripts in total RNA from whole blood of diagnosed t(9;22) positive CML patients expressing e13a2 and/or e14a2 fusion transcripts.
QuantideX qPCR BCR-ABL minor
The QuantideX qPCR BCR-ABL minor Kit, an in vitro diagnostic (IVD) assay, enables ultra-sensitive detection of BCR-ABL1 minor breakpoint (e1a2) transcripts from whole blood specimens.
Product is available in the following countries: